Wiener Privatklinik
Pourquoi choisir l'Autriche pour la thérapie au Lutétium-177 ?
Accédez à des solutions avancées de thérapie au Lutétium-177 dans des cliniques de confiance .
| Autriche | Turquie | Espagne | |
| Thérapie au lutétium-177 | de $35,000 | de $8,800 | de $12,000 |
Bookimed ne facture pas de frais supplémentaires pour les prix des Thérapie au lutétium-177. Les tarifs sont issus des listes de prix officielles des cliniques. Vous payez directement à la clinique lors de votre arrivée pour votre Thérapie au lutétium-177.
Bookimed s'engage pour votre sécurité. Nous ne travaillons qu'avec des établissements médicaux qui respectent des normes internationales élevées dans Thérapie au lutétium-177 et qui possèdent les licences nécessaires pour accueillir des patients internationaux dans le monde entier.
Bookimed offre une assistance experte gratuite. Un coordinateur médical personnel vous accompagne avant, pendant et après votre traitement, en résolvant tous les problèmes. Vous n'êtes jamais seul dans votre parcours de Thérapie au lutétium-177.
Lutetium-177 therapy is a targeted radioligand treatment using radioactive isotopes to destroy advanced cancer cells. This theranostic approach combines diagnostic imaging with precision beta radiation. It primarily treats metastatic castration-resistant prostate cancer and neuroendocrine tumors while sparing surrounding healthy tissue through short-range radiation delivery.
Bookimed Expert Insight: While many global clinics offer Lutetium-177, Austrian facilities like Wiener Privatklinik stand out for their diagnostic integration. They treat over 7,000 patients annually and utilize on-site Aeromedical Centers for same-morning pre-treatment exams. This efficiency significantly reduces the time international patients must stay abroad between diagnostic scans and their first infusion cycle.
Patient Consensus: Patients frequently report that while the treatment effectively reduces pain and lowers PSA levels, managing persistent dry mouth is a common practical challenge. The outpatient nature of the infusions allows for a much faster return to daily routines compared to traditional systemic chemotherapy.
Lutetium-177 therapy in Austria primarily treats advanced, metastatic castration-resistant prostate cancer and neuroendocrine tumors (NETs). Specialized nuclear medicine departments use Lu-177 PSMA to target prostate tumor cells and PRRT (Lutathera) for somatostatin-receptor positive gastroenteropancreatic tumors when surgery is not feasible.
Bookimed Expert Insight: While many countries treat Lutetium-177 as a secondary option, Austrian private clinics like Wiener Privatklinik coordinate these cases through multidisciplinary tumor boards. This ensures patients receive nuclear medicine expertise integrated with standard oncology. Their high volume of 12,000 annual patients supports faster access to specialized ligands like Pluvicto.
Patient Consensus: Patients emphasize that checking receptor status via PET scan is the critical first step. Most report manageable short-term fatigue and emphasize the importance of regular blood count monitoring between infusions.
Candidates for 177Lu-PSMA therapy are adults with advanced metastatic castration-resistant prostate cancer that has progressed after hormone therapy. Successful eligibility depends on high PSMA protein expression confirmed via PET scan and stable organ function to safely process systemic radionuclide radiation.
Bookimed Expert Insight: Austria provides a high-tier clinical environment for this therapy. Facilities like Wiener Privatklinik are globally ranked by Newsweek and focus on complex oncology. While the therapy is life-extending, Austrian specialists prioritize bone marrow health. They often require specific blood count thresholds before each of the 3–4 injections.
Patient Consensus: Patients emphasize that a positive PET scan is the critical first hurdle. Many report that while the treatment effectively manages symptoms, preparing for side effects like dry mouth or fatigue is essential.
Lutetium-177 therapy in Austria is administered via a 10–30 minute intravenous radioactive infusion. Patients first receive a kidney-protective amino-acid drip. Recovery involves 3–14 days of strict radiation precautions. Expect several days of fatigue and nausea as your body processes the radionuclide.
Bookimed Expert Insight: Clinics like Wiener Privatklinik leverage Austria's high global rank in nuclear medicine. Data shows hydration protocols are the biggest differentiator. Comprehensive centers use specific amino-acid blends. These reduce kidney radiation uptake. This protects organ function across multiple treatment cycles.
Patient Consensus: Patients emphasize preparing for a long day of hydration drips before the short infusion. Many recommend bringing books or music and planning for significant fatigue during the first week.
Austria offers Lutetium-177 therapy at specialized nuclear medicine centers in Vienna, Salzburg, and Innsbruck. Leading facilities include Wiener Privatklinik and University Hospital Vienna (AKH). These centers utilize advanced PSMA and DOTATATE radioligand therapies for metastatic prostate cancer and neuroendocrine tumors.
Bookimed Expert Insight: Wiener Privatklinik stands out because it combines private hospital comfort with elite university-level expertise. While AKH serves massive patient volumes, WPK offers 4.6-rated personalized care with 300 specialized doctors. This balance is ideal for international patients seeking fast access to nuclear medicine without the wait times typical of large public research hubs.
Patient Consensus: Patients emphasize that Lutetium-177 requires a multidisciplinary tumor board review rather than routine referral. They advise verifying if a facility has a dedicated nuclear medicine department before booking travel.